In the letter to the Editor, entitled “Role of hemagglutinin esterase protein in neurological manifestation of COVID-19”, the authors [1] appear to indicate that a role was attributed to hemagglutinin esterase (HE) in the coronavirus disease 2019 (COVID-19) neurological manifestation in a recent review article [2]. However, in this review HE is mentioned once but there is no discussion on its function. In addition, there is no speculation on HE’s role in COVID-19 and specifically on the neurological manifestations of this infection in the review [2].
At the time the manuscript of the review was prepared, there were articles, which contain diagrammatic figures of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) with HE and/or descriptions of HE as a structural component [3–5]. Also, a more recent article described HE as a structural component of SARS-CoV-2, and there is, also, a diagrammatic figure of SARS-CoV-2 with HE [6]. Thus, there is still ongoing confusion on HE’s presence in SARS-CoV-2.
At the time of the COVID-19 outbreak, information on the virus genomic structure, membrane proteins and their functions were rapidly evolving. Indeed, the completion of the genetic sequencing of SARS-CoV-2 led to the production of effective vaccines, and a better understanding of the virus lineage and the origin of its variants. Thus, the information in the literature on whether HE is present in this virus may be due to the evolving knowledge on the virus, including its structure, function of its various membrane proteins and the etiology of COVID-19.
However, the references used to support the statement on the presence of HE in SARS-CoV-2 were inadvertently removed during the editing process of the review [2]. These are now included in this letter [3, 4].
Acknowledgements
Funding from the NIH (AG057574 and AG050212 to RD).
Authors' contributions
RD wrote the letter. The author read and approved the final manuscript.
Funding
Availability of data and materials
Not applicable.
Declarations
Ethics approval and consent to participate
Not applicable.
Consent for publication
Not applicable.
Competing interests
The author declares that there are no competing interests.
Footnotes
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
References
- 1.Zandi M, Karami H, Soltani S. Role of hemagglutinin esterase protein in neurological manifestation of COVID-19. Fluids Barriers CNS. 2021;18:39. doi: 10.1186/s12987-021-00271-2. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.McQuaid C, Brady M, Deane R. SARS-CoV-2: is there neuroinvasion? Fluids Barriers CNS. 2021;18(1):1–21. doi: 10.1186/s12987-021-00267-y. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.Infantino M, Damiani A, Gobbi FL, Grossi V, Lari B, Macchia D, et al. Serological assays for SARS-CoV-2 infectious disease: benefits, limitations and perspectives. Isr Med Assoc J. 2020;22:203–210. [PubMed] [Google Scholar]
- 4.Lahlou Y, El AB, Bamhaoud T. Genomic and molecular analysis of SARS-CoV-2 and the possible strategies of Covid-19 treatment—a review. IOSR J Pharm Biol Sci. 2020;13:39–47. [Google Scholar]
- 5.Kim CH. Sars-cov-2 evolutionary adaptation toward host entry and recognition of receptor o-acetyl sialylation in virus–host interaction. Int J Mol Sci. 2020;21:1–34. doi: 10.3390/ijms21124549. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.Bagheri HS, Karimipour M, Heidarzadeh M, Rajabi H, Sokullu E, Rahbarghazi R. Does the global outbreak of COVID-19 or other viral diseases threaten the stem cell reservoir inside the body? Stem Cell Rev Rep. 2021;17:214–230. doi: 10.1007/s12015-020-10108-4. [DOI] [PMC free article] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Data Availability Statement
Not applicable.